Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press104410.17650/1726-9776-2008-4-4-61-65DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряClinical application of FISH method in the early diagnostics of superficial bladder cancerКлиническое применение FISH-метода в ранней диагностике поверхностного рака мочевого пузыряSevankaevA. V.СеванькаевА. В.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

LushnikovE. F.ЛушниковЕ. Ф.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

KaryakinO. B.КарякинО. Б.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

MikhailovaG. F.МихайловаГ. Ф.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

GorbanN. A.ГорбаньН. А.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

BashkatovS. V.БашкатовС. В.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

GoloubE. V.ГолубЕ. В.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

ShkavrovaT. G.ШкавроваТ. Г.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

TsepenkoV. V.ЦепенкоВ. В.
Russian Federation

Department of radiotherapy and surgery of urologic disorders, clinical morphologic department, laboratory of molecular cytogenetics

Отделение лучевого и хирургического лечения урологических заболеваний, клинико-морфологический отдел, лаборатория молекулярной цитогенетики

Medical Radiological Research Centre of Russian Academy of Medical SciencesГУ МРНЦ РАМН301220084461651302202013022020https://oncourology.abvpress.ru/oncur/article/view/1044

Patients with primary diagnosis of bladder cancer (42 persons) were studied. FISH analysis performed in all patients showed the following results: 39 (93%) patients were FISH positive and 3 (7%) were FISH negative. The molecular cytogenetic criterion for determining the grade of differentiation of Ta and T1 tumors — chromosomal hyperploidy in morphologically abnormal cells, was suggested. All patients demonstrating increased amount (more than 26%) of abnormal cell with hyperploidy of chromosomes 3, 7 and 17 were found to have high grade malignancies.

.

1. Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М.: Вердана; 2001.Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М.: Вердана; 2001.2. Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57(4):811—5.Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57(4):811—5.3. Knowles M.A. Molecular pathology of solid tumours: translating research into clinical practice. Introduction and overview. J Clin Pathol Mol Pathol 2001;54:215—21.Knowles M.A. Molecular pathology of solid tumours: translating research into clinical practice. Introduction and overview. J Clin Pathol Mol Pathol 2001;54:215—21.4. Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Molec Diag 2000;2(3):116—23.Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Molec Diag 2000;2(3):116—23.5. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3(4):507—19.Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3(4):507—19.6. Junker K., Fritsch T., Hartmann A. et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114(3—4):279—83.Junker K., Fritsch T., Hartmann A. et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114(3—4):279—83.7. Kang J.U., Koo S.H., Jeong T.E. et al. Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet 2006;164(1):32—8.Kang J.U., Koo S.H., Jeong T.E. et al. Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet 2006;164(1):32—8.8. Marin-Aguilera M., Mengual L., Ribal M. et al. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 2007;51:409—15.Marin-Aguilera M., Mengual L., Ribal M. et al. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 2007;51:409—15.9. Mian C., Lodde M., Comploj E. et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urotelial carcinoma. Cytopathology 2003;14(6):338—42.Mian C., Lodde M., Comploj E. et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urotelial carcinoma. Cytopathology 2003;14(6):338—42.10. Moonen P.M., Merkh G.F., Peelen P. et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007;51:1275—80.Moonen P.M., Merkh G.F., Peelen P. et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007;51:1275—80.11. Sarosdy M.F., Kahn P.R., Ziffer M.D. et al. Use of a multi target fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. Urology 2006;176(1):44—7.Sarosdy M.F., Kahn P.R., Ziffer M.D. et al. Use of a multi target fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. Urology 2006;176(1):44—7.12. Scacel M., Fahmy M., Brainard J. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majoirity of patients with bladder cancer and atypical or negative urine cytology. Urology 2003;169(6):2101—5.Scacel M., Fahmy M., Brainard J. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majoirity of patients with bladder cancer and atypical or negative urine cytology. Urology 2003;169(6):2101—5.13. Veeramachaneni R., Nordberg M.L., Shi R. et al. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28(6):301—7.Veeramachaneni R., Nordberg M.L., Shi R. et al. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28(6):301—7.14. Строганова А.М., Хачатурян А.В. Возможности применения флюоресцентной in situ гибридизации в диагностике рака мочевого пузыря. Арх патол 2006;(5):43—6.Строганова А.М., Хачатурян А.В. Возможности применения флюоресцентной in situ гибридизации в диагностике рака мочевого пузыря. Арх патол 2006;(5):43—6.15. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eds. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn. Lyon: IARCPress; 2004.World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eds. J.N. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn. Lyon: IARCPress; 2004.